SEATTLE, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2024. Reported total operating expenses for the fourth quarter of 2024 were $20.0 million, roughly equal to the fourth quarter of 2023, and $0.9 million above last... Read More

SEATTLE, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc . (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the TD Cowen 45 th Annual Healthcare Conference. Nautilus’ management is scheduled to participate in a fireside chat on Monday, March 3, 2025, at 1:50 p.m. Eastern Time.... Read More

SEATTLE, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2024 before market open on Thursday, February 27, 2025. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30... Read More

SEATTLE, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced Nautilus co-founder and Chief Scientist Parag Mallick, Ph.D., was bestowed the 2024 Distinguished Investigator... Read More

SEATTLE, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Inaugural Guggenheim Healthcare Conference. Nautilus’ management is scheduled to participate in a fireside chat on Wednesday, November 13, 2024, at 9:30 a.m. Eastern Time. Interested parties may access... Read More

SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2024. “I’m excited about the expanding opportunity I see for proteomics and am pleased with the progress we’re making as a business,” said Sujal Patel, CEO of Nautilus. “We... Read More

SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the third quarter 2024 before market open on Tuesday, October 29, 2024. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to... Read More

SEATTLE, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for comprehensively quantifying the proteome, today announced the appointment of Kentaro (Ken) Suzuki as Chief Marketing Officer. Mr. Suzuki joins Nautilus... Read More

SEATTLE, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today announced the company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Nautilus management is scheduled to participate in a fireside chat on Wednesday, September 4, 2024, at 7:00 a.m. Eastern Time. Interested... Read More

SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2024. “In Q2, we saw continued progress against core development goals for each of the components of our platform,” said Sujal Patel, CEO of Nautilus. “We believe we are pioneering a... Read More

SEATTLE, July 09, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the second quarter 2024 before market open on Tuesday, July 30, 2024. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to... Read More

SEATTLE, May 23, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Goldman Sachs 45th Annual Healthcare Conference. Nautilus’ management is scheduled to participate in a fireside chat on Monday, June 10, 2024, at 8:40 a.m. Eastern Time. Interested parties may access a... Read More

SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024. “We continued to make solid progress against our core development goals in Q1,” said Sujal Patel, CEO of Nautilus. “We remain incredibly focused on increasing the scale, stability,... Read More

SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to... Read More

SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023. “2023 was a year of significant accomplishment and foundational progress for Nautilus; progress that will continue to build our momentum as we move through 2024... Read More

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the TD Cowen 44th Annual Healthcare Conference. Nautilus’ management is scheduled to participate in a fireside chat on Wednesday, March 6 th at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. Interested... Read More

SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2023 before market open on Wednesday, February 28, 2024. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30... Read More

SEATTLE, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced Nautilus co-founder and Chief Scientist Parag Mallick, Ph.D., was selected as the 2024 recipient of the Gilbert S. Omenn Computational Proteomics Award presented by the US Human Proteome Organization (US HUPO). The... Read More

SEATTLE, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the expansion of its research and development senior leadership team with the appointment of Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development. Dr. Huber brings to Nautilus over 20... Read More

SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2023. “I’m very pleased with the progress Nautilus made in Q3 as we continue our drive towards commercial readiness”, said Sujal Patel, CEO of Nautilus. “Continuing to increase the... Read More

SEATTLE, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter before market open on Tuesday, October 31, 2023. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to... Read More

SEATTLE, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences: Morgan Stanley 21 st Annual Global Healthcare Conference in New York, NY Management is scheduled to participate in a fireside chat on Wednesday, September 13 th at 7:50... Read More

SEATTLE, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences: Canaccord 43 rd Annual Growth Conference in Boston, MA Management will participate in “The Next Generation of Proteomics from the Research and Clinical Perspectives”... Read More

SEATTLE, Wash., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2023. “I’m excited by the solid progress we made in Q2 against some of our foundational scientific and development goals and in the ways we continue to prepare ourselves for our... Read More

SEATTLE, July 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the second quarter before market open on Wednesday, August 2, 2023. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to... Read More

SEATTLE, May 24, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences: Jefferies 2023 Healthcare Conference in New York, NY Fireside chat on Thursday, June 8 th at 1:00 p.m. Eastern Time Goldman Sachs 44 th Annual Global Healthcare Conference... Read More

SEATTLE, May 02, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2023. Recent Highlights Announced the three winners of Nautilus’ First Access Challenge, representing a diverse set of investigators and spanning a wide range of areas of study across... Read More

SEATTLE, April 18, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the first quarter before market open on Tuesday, May 2, 2023. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss... Read More

SEATTLE, March 23, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the upcoming B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference. Nautilus’ management is scheduled to participate in a fireside chat on Thursday, April 6 th at... Read More

SEATTLE, March 07, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced the selection of three research proposals submitted to the First Access Challenge, a competition for furthering high-impact work in proteomics. The winning projects were also revealed at the US HUPO (Human Proteome... Read More

SEATTLE, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2022. Recent Highlights Announced a strategic partnership with the Translational Genomics Research Institute (TGen) to explore the utility of the Nautilus platform for... Read More

SEATTLE, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the upcoming 43 rd Annual Cowen Health Care Conference. Nautilus’ management is scheduled to participate in a fireside chat on Monday, March 6 th at 11:50 a.m. Pacific Time / 2:50 p.m. Eastern Time.... Read More

SEATTLE, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2022 before market open on Thursday, February 23, 2023. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30... Read More

SEATTLE, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the opening of its new office space at University Town Center in San Diego, California. The initial... Read More

SEATTLE, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, and the Translational Genomics Research Institute (TGen), part of City of Hope, today announced a partnership to explore the utility of the Nautilus platform by studying specific protein targets in diffuse intrinsic pontine glioma (DIPG), a rare and often... Read More